What the FDA labels say about taking them together
Fluoxetine and rasagiline
Rasagiline's FDA label of June 30, 2020 names fluoxetine in its warnings and precautions section; fluoxetine's label does not name rasagiline itself but warns about its class (MAO inhibitors).
Check it at the source: the fluoxetine FDA label on DailyMed (effective January 8, 2026, Dista Products Company); the rasagiline FDA label on DailyMed (effective June 30, 2020, Teva Pharmaceuticals USA, Inc.).
What does the fluoxetine label say about rasagiline?
Fluoxetine's label does not name rasagiline itself; it warns about its class (MAO inhibitors):
Fluoxetine label, contraindicationsInhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with PROZAC or within 5 weeks of stopping treatment with PROZAC is contraindicated because of an increased risk of serotonin syndrome.
Fluoxetine label, contraindicationsStarting PROZAC in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.10 ) and Warnings and Precautions ( 5.2 )].
Source: FDA drug label (Prozac), NDA018936 (Eli Lilly And Co), as published by Dista Products Company, effective January 8, 2026 (SPL set c88f33ed-6dfb-4c5e-bc01-d8e36dd97299), via openFDA; the full label on DailyMed
What does the rasagiline label say about fluoxetine?
Rasagiline label, warnings and precautionsBecause of the long half-lives of certain antidepressants (e.g., fluoxetine and its active metabolite), at least five weeks (perhaps longer, especially if fluoxetine has been prescribed chronically and/or at higher doses) should elapse between discontinuation of fluoxetine and initiation of rasagiline [see Drug Interactions ( 7.5 )].
Source: FDA drug label (Rasagiline), Teva Pharmaceuticals USA, Inc., effective June 30, 2020 (SPL set e802c83c-e581-4a11-b83d-1df47120078d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fluoxetine | Rasagiline | |
|---|---|---|
| Labeled for | Depression, Anxiety, Bipolar disorder | Parkinson's disease |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0519 per capsule 40 mg capsule | $0.521 per tablet 0.5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once